Curaleaf Holdings (CURLF) Liabilities and Shareholders Equity (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Liabilities and Shareholders Equity of $2.8 billion for Q4 2025, down 3.54% year-over-year from $2.9 billion in Q4 2024, and down 3.54% quarter-over-quarter from $2.9 billion in Q4 2024.
Curaleaf Holdings (CURLF) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $2.8 billion for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 3.54% year-over-year to $2.8 billion; the TTM figure through Mar 2026 stood at $2.8 billion (down 68.76% YoY), while the FY2025 annual figure was $2.8 billion, down 3.54% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $2.8 billion, down from $2.9 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $3.5 billion in Q1 2022, with the low at $737.0 million in Q4 2021.
- The 5-year median for Liabilities and Shareholders Equity is $3.1 billion (2023), against an average of $2.9 billion.
- Peak annual rise in Liabilities and Shareholders Equity reached 34.57% in 2021, while the deepest fall reached 68.84% in 2021.
- Curaleaf Holdings' Liabilities and Shareholders Equity stood at $737.0 million in 2021, then jumped by 381.6% to $3.5 billion in 2022, then declined by 12.76% to $3.1 billion in 2023, then retreated by 4.74% to $2.9 billion in 2024, then slipped by 3.54% to $2.8 billion in 2025.
- Business Quant data shows CURLF's Liabilities and Shareholders Equity at $2.8 billion in Q4 2025, $2.9 billion in Q4 2024, and $3.1 billion in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Curaleaf Holdings | 2.51 Bn | 2.42 Bn | 169.91 Mn | 2.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.81 Bn |
| Dec 31, 2025 | 2.85 Bn |
| Dec 31, 2024 | 2.95 Bn |
| Sep 30, 2024 | 3.07 Bn |
| Jun 30, 2024 | 3.08 Bn |
| Dec 31, 2023 | 3.10 Bn |
| Sep 30, 2023 | 3.23 Bn |
| Jun 30, 2023 | 3.30 Bn |
| Mar 31, 2022 | 3.55 Bn |
| Dec 31, 2021 | 737.03 Mn |
| Sep 30, 2021 | 3.17 Bn |
| Jun 30, 2021 | 3.15 Bn |
| Mar 31, 2021 | 2.68 Bn |
| Dec 31, 2020 | 2.37 Bn |
| Sep 30, 2020 | 2.36 Bn |
| Dec 31, 2019 | 736.93 Mn |